Ottawa Allergy Research Corporation

06/18/2025

🎉 What an exciting May it’s been! 🎉

We kicked off Dosing Day for our gene therapy clinical trial targeting Hereditary Angioedema (HAE)—a rare disease that deserves big breakthroughs! 💉🧬

It’s not every day you get to be part of something this groundbreaking… and we are pumped to help move science forward, one patient, one dose, one discovery at a time!

Stay tuned… the future of rare disease treatment is getting brighter! ✨💙

06/12/2025

Recruiting participants with Type I or Type II HAE for Astria ORBIT a every 3 or 6 month prophylactic treatment in the management of Hereditary Angioedema.

07/09/2024

Look who made it on the Aslan's Newsletter!! 👍👏🤩

04/08/2024

Viewing party!!!!🌘🌒

02/28/2024

New Opportunity for Peanut Allergy Treatment!

https://vitesseallergystudy.com/

02/21/2024

If you have been diagnosed with Eosinophilic Esophagitis (EoE), or you know of someone, this clinical trial might be for you. We are still looking for PARTICIPANTS. Please give us a call for more information.

The Ottawa Allergy Research Corporation currently carries out Phase I, II, III and IV clinical trial

12/22/2023

Wishing everyone a safe and happy Holidays!!! - OARC Team

05/19/2023

NOW ENROLLING! We are excited to be accepting participants in the VITESSE Phase 3 pediatric peanut allergy study.
To be eligible to participate in this study, individuals must be:
• Between 4 to 7 years of age
• Diagnosed with peanut allergy
• Currently following a strict peanut-free diet
Other inclusion/exclusion criteria will apply. Please contact us to learn more!

07/13/2022

Ontario Public Health just announced the approval of the 2nd booster to 18 and above. Our sister company is offering the vaccine. Please see their page for details.

Are you employed and planning to get your COVID-19 vaccine or booster? Sign up to complete a research survey each night for a week following your dose and receive up to $245. Visit/Call Red Maple Trials at (613) 368-4320 EXT.100 and mention the VIP Survey study.

06/08/2022

Important news!

Health Canada approves the oral treatment Orladeyo for HAE prophylaxis treatment.

We are very happy to be a part of another important milestone in HAE. We thank all the study coordinators, doctors and most especially the patients that took part in this clinical trial.

https://www.globenewswire.com/en/news-release/2022/06/06/2456568/29446/en/BioCryst-Announces-Health-Canada-has-Authorized-ORLADEYO-berotralstat-the-Only-Oral-Treatment-for-the-Prevention-of-Hereditary-Angioedema-Attacks.html

RESEARCH TRIANGLE PARK, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has...

06/08/2022

Another successful clinical trial for moderate to severe Atopic Dermatitis patients.

"80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed"

https://investor.lilly.com/news-releases/news-release-details/eight-out-ten-patients-maintained-skin-clearance-one-year-lillys

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

05/21/2022